Portage, Michigan, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2025 Wells Fargo Securities Healthcare Conference on Thursday, September 4, at the Encore Boston Harbor.
Andy Pierce, Group President, MedSurg and Neurotechnology, and Jason Beach, Vice President, Finance and Investor Relations will participate in a Fireside Chat scheduled for 2:15 pm Eastern Time.
A live audio webcast of the session, along with a replay, will be accessible on Stryker’s official website at www.stryker.com. The recording will be archived on the Investor Relations section of the site.
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.
Contacts
For investor inquiries:
Jason Beach, Vice President, Finance and Investor Relations at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it.
For media inquiries:
Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$394.22 |
Daily Change: | 9.39 2.44 |
Daily Volume: | 868,660 |
Market Cap: | US$150.710B |
July 31, 2025 May 01, 2025 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load